- In April 2023, Baxter International Inc. announced the U.S. launch of its next-generation Floseal Hemostatic Matrix, designed to provide more rapid and reliable bleeding control in complex surgical procedures. The updated formulation offers enhanced viscosity and delivery precision, enabling surgeons to apply the product more efficiently in minimally invasive environments. This development reinforces Baxter’s leadership in surgical hemostasis and highlights the growing demand for advanced, easy-to-use solutions in high-pressure surgical settings
- In March 2023, Ethicon, a Johnson & Johnson MedTech company, expanded its SURGICEL® Powder product line in the U.S. with an advanced applicator designed for laparoscopic and robotic-assisted surgeries. The innovation addresses the challenges of accessing bleeding sites in minimally invasive procedures and demonstrates Ethicon’s commitment to supporting evolving surgical techniques with adaptable and effective hemostatic solutions
- In February 2023, Teleflex Incorporated introduced its Hem-o-lok Polymer Ligation System upgrade in U.S. surgical centers, emphasizing improved control and enhanced visualization for vascular ligation in minimally invasive surgeries. This advancement aims to optimize intraoperative workflow while maintaining a high standard of hemostasis. The product’s U.S. rollout underlines Teleflex’s continued focus on procedural safety and surgeon convenience
- In January 2023, Medcura Inc., in collaboration with the U.S. Department of Defense, announced clinical development progress on its next-generation hemostatic gel, targeting battlefield trauma and emergency surgical applications. The gel formulation, which rapidly stops bleeding without relying on clotting factors, is part of a broader strategy to develop hemostats suited for both civilian and military environments. This highlights a rising trend in dual-use hemostatic innovations aimed at high-risk scenarios
- In January 2023, Z-Medica LLC (a part of Teleflex) reported increased adoption of its QuikClot® Combat Gauze® by emergency departments and trauma centers across the U.S., driven by its proven efficacy in critical bleeding control. Originally developed for military use, the gauze is now widely implemented in civilian trauma care, emphasizing the growing crossover between military-grade hemostatic solutions and advanced hospital-based applications
